Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redefining topological robustness in optical polarization fields through a generalized skyrmion number.

Nature communications·2026
Same author

Comparative analysis of morphology and chloroplast genomes in endangered plant <i>Madhuca pasquieri</i> and two congeneric plants: revealing phylogenetic relationships.

Frontiers in plant science·2026
Same author

AQP4 and MOG Characterize the Autoantibody Landscape of Checkpoint Blockade-Induced Optic Neuritis.

Annals of neurology·2026
Same author

CT - derived fractional flow reserve can predict recurrent ischemia in patients with MCA stenosis.

Frontiers in neurology·2026
Same author

Reliability and Consistency Analysis of Multiple Instruments for Scoliosis Screening in Adolescent Males: A Comparative Study of Instrument Accuracy.

Studies in health technology and informatics·2026
Same author

Motionless speckle reduction using a three-dimensional printed micro-optical structure.

Optics express·2026

Related Experiment Video

Updated: Jun 26, 2025

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.0K

HIV-Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety-Net Setting.

Matthew S Durstenfeld1, Anjali Thakkar2, Diane Jeon2

  • 1Division of Cardiology at ZSFG and Department of Medicine, University of California, San Francisco (UCSF), USA.

Medrxiv : the Preprint Server for Health Sciences
|May 20, 2024
PubMed
Summary

People with HIV (human immunodeficiency virus) and heart failure (HF) face higher mortality rates, with deaths often linked to non-cardiovascular causes like substance use. This highlights critical disparities in care within safety-net systems.

Keywords:
Clinical OutcomesHIVHeart FailureMortality

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.5K
Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

16.6K

Related Experiment Videos

Last Updated: Jun 26, 2025

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.0K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.5K
Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

16.6K

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • Human immunodeficiency virus (HIV) is linked to increased heart failure (HF) risk.
  • Understanding HF phenotypes and outcomes in people with HIV (PWH) within safety-net systems is crucial due to their significant healthcare utilization.

Approach:

  • Utilized an electronic health record cohort of individuals with HF in a municipal safety-net system (2001-2019).
  • Compared HF phenotypes, mortality, HF hospitalizations, and causes of death between individuals with and without HIV.
  • Linked data to the National Death Index Plus for comprehensive outcome assessment.

Key Points:

  • PWH were diagnosed with HF a decade earlier on average and had a higher proportion with reduced ejection fraction.
  • HIV was associated with a 55% increased risk of all-cause mortality and lower odds of HF hospitalization.
  • Causes of death in PWH with HF were less frequently cardiovascular and more often attributed to substance use and HIV-related conditions.

Conclusions:

  • In safety-net settings, HIV infection is associated with elevated mortality among HF patients.
  • Despite lower HF hospitalization rates, PWH experience higher overall mortality due to non-cardiovascular causes.
  • Findings underscore the need for integrated care addressing both HIV and cardiovascular health in vulnerable populations.